SELLAS Life Sciences Group, Inc. Share Price
Stocks
SLS
US81642T2096
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
01:30:00 28/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 12.17 USD | +7.32% |
|
+16.02% | +222.81% |
| 25/09 | SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer | CI |
| 14/09 | Top Premarket Decliners | MT |
| Market Cap | 245.77Cr 220.81Cr 203.7Cr 184.7Cr 345.3Cr 23TCr 349.67Cr 2.44TCr 971.4Cr 12TCr 922.47Cr 902.66Cr 39TCr | P/E 2026 * |
-59.4x | P/E 2027 * | -128x |
|---|---|---|---|---|---|
| Enterprise Value | 245.77Cr 220.81Cr 203.7Cr 184.7Cr 345.3Cr 23TCr 349.67Cr 2.44TCr 971.4Cr 12TCr 922.47Cr 902.66Cr 39TCr | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 46.3x |
| Free-Float |
99.08% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SLS | Delayed | |
CBOE
| SLS | Real-time | |
|
Tradegate
| RXK3 | Real-time | |
|
Boerse Muenchen
| RXK3 | Real-time | |
|
Börse Stuttgart
| RXK3 | Delayed | |
|
Deutsche Boerse AG
| RXK3 | Delayed | |
|
Xetra
| RXK3 | Delayed |
Last Transcript: SELLAS Life Sciences Group, Inc.
| 1 day | +7.32% | ||
| 1 week | +16.02% | ||
| Current month | -1.14% | ||
| 1 month | +4.82% | ||
| 3 months | +7.51% | ||
| 6 months | +172.87% | ||
| Current year | +222.81% |
| 1 week | 11.08 |  | 12.37 |
| 1 month | 9.75 | | 12.7 |
| Current year | 3.23 | | 15.88 |
| 1 year | 1.39 | | 15.88 |
| 3 years | 0.5 | | 15.88 |
| 5 years | 0.5 | | 15.88 |
| 10 years | 0.5 | | 554.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Angelos Stergiou
CEO | Chief Executive Officer | 50 | 29/12/2017 |
John Burns
DFI | Director of Finance/CFO | 41 | 30/12/2017 |
Stacy Yeung
CMP | Compliance Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Angelos Stergiou
BRD | Director/Board Member | 50 | 29/12/2017 |
John Varian
CHM | Chairman | 66 | 01/06/2024 |
| Director/Board Member | 69 | 29/12/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 07/01/26 | Free | Executive/Senior Manager | 3,00,000 | 0.2106% | ||
| 07/01/26 | Free | Director | 50,000 | 0.0351% | ||
| 07/01/26 | Free | Chief Financial Officer | 3,00,000 | 0.2106% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.32% | +16.02% | +511.56% | +1,222.83% | 229.01Cr | |
| -3.10% | -3.43% | +36.29% | +67.69% | 6.53TCr | |
| +0.33% | +7.26% | +11.51% | +77.95% | 5.46TCr | |
| +0.16% | +3.69% | +8.39% | +101.27% | 5.36TCr | |
| -0.75% | +2.13% | +23.14% | +47.25% | 4.5TCr | |
| -1.30% | -1.11% | +17.77% | +120.71% | 4.22TCr | |
| +1.26% | +2.23% | +241.81% | +835.31% | 3.94TCr | |
| -0.74% | -4.84% | +14.53% | +44.45% | 3.27TCr | |
| -2.70% | -7.34% | +23.17% | +0.36% | 2.4TCr | |
| +1.11% | +17.90% | +56.87% | +47.78% | 2.65TCr | |
| Average | +0.16% | +2.59% | +94.50% | +256.56% | 3.86TCr | |
| Weighted average by Cap. | -0.67% | +1.76% | +47.93% | +155.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 5.31Cr 4.77Cr 4.4Cr 3.99Cr 7.46Cr 504.95Cr 7.55Cr 53Cr 21Cr 264.29Cr 20Cr 20Cr 838.57Cr |
| Net income | -3.83Cr -3.44Cr -3.17Cr -2.88Cr -5.38Cr -364.21Cr -5.45Cr -38Cr -15Cr -190.63Cr -14Cr -14Cr -604.85Cr | -2.14Cr -1.92Cr -1.77Cr -1.61Cr -3Cr -203.3Cr -3.04Cr -21Cr -8.45Cr -106.41Cr -8.02Cr -7.85Cr -337.62Cr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/26/27 | $12.17 | +7.32% | 61,05,102 |
| 26/26/26 | $11.34 | -1.73% | 32,14,377 |
| 23/26/23 | $11.54 | +1.67% | 32,79,155 |
| 22/26/22 | $11.35 | -6.51% | 65,12,781 |
| 21/26/21 | $12.14 | +1.34% | 56,57,050 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SLS Stock
Select your edition
All financial news and data tailored to specific country editions
